Galectin Therapeutics
NASDAQ: GALTNorcross, US · Nevada corporation
Galectin Therapeutics develops galectin-3 inhibitor therapies, including its lead carbohydrate-based drug belapectin (GR-MD-02), for patients with chronic liver disease and cancer. Its lead program targets MASH (non-alcoholic steatohepatitis) cirrhosis and fibrosis.
Founders & leadership
Board
KD
Kevin D FreemanBoard director
GS
Gilbert S OmennBoard director
AR
Arthur R GreenbergBoard director
MR
Marc RubinBoard director
JG
John G. MauldinBoard director
GF
Gilbert F AmelioBoard director
SG
Steven G. PrelackBoard director
Reported raises · per SEC filings
Form D private placements$4.5M disclosed across 2 of 3 rounds · 2015–2016
▶$3MraisedJan 2017 · 5 investors · PharmaceuticalsRule 506(b)
▶$3MraisedJan 2017 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin D FreemanDirector
- Gilbert S OmennDirector
- Harold H. ShlevinExecutive Officer
- Theodore ZuconniDirector
- Steven G. PrelackDirector
- Gilbert F AmelioDirector
- Marc RubinDirector
- James C CzirrDirector
- John G. MauldinDirector
- Peter G TraberExecutive Officer, Director
- Jack W CallicuttExecutive Officer
- Arthur R GreenbergDirector
- Offering amount
- $10M
- Amount sold
- $3M
- First sale
- Dec 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.5MraisedSep 2016 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedSep 2016 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marc RubinDirector
- Jack W CallicuttExecutive Officer, Director
- James C CzirrDirector
- Gilbert S OmennDirector
- Peter G TraberExecutive Officer, Director
- Steven G. PrelackDirector
- John G. MauldinDirector
- Arthur R GreenbergDirector
- Kevin D FreemanDirector
- Gilbert F AmelioDirector
- Offering amount
- $12M
- Amount sold
- $1.5M
- First sale
- Sep 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶Undisclosed amountofferedDec 2015 · 6 investors · PharmaceuticalsRule 506(b)
▶Undisclosed amountofferedDec 2015 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin D FreemanDirector
- Jack W CallicuttExecutive Officer, Director
- James C CzirrExecutive Officer, Director
- Gilbert S OmennDirector
- Arthur R GreenbergDirector
- Peter G TraberExecutive Officer, Director
- Marc RubinDirector
- John G. MauldinDirector
- Gilbert F AmelioDirector
- Steven G. PrelackDirector
- Sales commissions
- $588.6K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Nov 2015
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Robinhood31 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits29 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Seeking Alpha27 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Galectin Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Galectin Therapeutics do?
- Galectin Therapeutics develops galectin-3 inhibitor therapies, including its lead carbohydrate-based drug belapectin (GR-MD-02), for patients with chronic liver disease and cancer. Its lead program targets MASH (non-alcoholic steatohepatitis) cirrhosis and fibrosis.
- Who founded Galectin Therapeutics?
- Galectin Therapeutics was founded by James C Czirr.
- How much funding has Galectin Therapeutics raised?
- Galectin Therapeutics has disclosed $4.5M raised across 2 of its 3 known rounds.
- Where is Galectin Therapeutics headquartered?
- Galectin Therapeutics is headquartered in Norcross, US.